Comparative Pharmacology
Head-to-head clinical analysis: SELENIUM SULFIDE versus TOLAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELENIUM SULFIDE versus TOLAK.
SELENIUM SULFIDE vs TOLAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selenium sulfide is an antifungal and cytostatic agent. It reduces sebum production and inhibits the growth of Malassezia species by interfering with fungal lipid metabolism and cell wall synthesis. The exact molecular mechanism is not fully elucidated.
TOLAK (tazarotene) is a retinoid prodrug that is converted to its active metabolite tazarotenic acid, which binds selectively to retinoic acid receptors (RARs) such as RARβ and RARγ; this modulates gene expression involved in cell proliferation, differentiation, and inflammation.
Topical: 2.5% lotion or shampoo applied to affected area once daily for 7 days; 1% shampoo used once or twice weekly for maintenance.
Adults: 200 mg orally twice daily.
None Documented
None Documented
Not established; due to negligible systemic absorption, a terminal half-life is not clinically relevant. If absorbed, selenium has a long biological half-life of approximately 65–115 days due to incorporation into selenoproteins.
The terminal elimination half-life of fluorouracil is approximately 10-20 minutes due to rapid catabolism by dihydropyrimidine dehydrogenase. Clinically, this short half-life necessitates continuous infusion for sustained systemic exposure.
Selenium sulfide is minimally absorbed after topical application. The small absorbed fraction is excreted renally as selenite or selenate, with fecal excretion of unabsorbed drug accounting for >90% of the dose.
Tolak (fluorouracil) is primarily eliminated via metabolism; less than 10% is excreted unchanged in urine. Fecal excretion accounts for approximately 10-20% of the administered dose.
Category A/B
Category C
Antifungal / Antiseborrheic
Antifungal